Scroll To Top




The Food and Drug Administration has approved a new, second-generation nonnuke, Tibotec's Intelence (etravirine), for use in salvage therapy. Studies have shown the drug, dosed as two tablets twice a day, is effective when started with other salvage medications or when replacing a failing nonnuke in an otherwise potent regimen. -------------------- Epzicom is now recommended as a preferred first-line therapy in federal HIV treatment guidelines, upgrading it from endorsement as an acceptable alternative first-line treatment. -------------------- Switching from another protease inhibitor to Reyataz can cut a patient's cardiovascular risks, according to a study in the January online edition of HIV Medicine. -------------------- The nonnuke Viramune significantly lowers the risk of liver damage in people coinfected with HIV and hepatitis C, says a study in the January 1 issue of Clinical Infectious Diseases. -------------------- Pfizer has licensed entry inhibitor Selzentry to the International Partnership for Microbicides, which will study ways to make the drug into a vaginal microbicide women can use to lower their risk of HIV infection. -------------------- Successful antiretroviral therapy reduces the risk of lung disease and other respiratory illnesses by dramatically lowering HIV levels in the lungs, according to the January 1 issue of The Journal of Infectious Diseases. -------------------- A combination of fish-oil supplements and the lipid-lowering drug Tricor better reduces triglyceride levels than either treatment alone, researchers report in the January 29 online edition of the Journal of Acquired Immune Deficiency Syndromes.

Out Subscription Lil Nas XAdvocateChannel promotion

From our Sponsors

Most Popular

Fifth Person Cured of HIV

Latest Stories